Benign hepatocyte line and hepatoma cell lines were used to perform in vitro studies to explore the hepatocyte-based TLR-4/IL-17A signaling and potential therapeutic targets against NASH-HCC transition. Here, IL17A is linked to hepatocellular carcinoma.